



INSTITUTE OF HUMAN VIROLOGY



UNIVERSITY of MARYLAND
SCHOOL OF MEDICINE

IHV CO-FOUNDERS

Robert C. Gallo
Director
William A. Blattner
Associate Director
Robert R. Redfield
Associate Director

BOARD OF ADVISORS

Terry Lierman, (Chair)
Summit Global Ventures
Peter Angelos
The Law Offices of Peter Angelos
Robert Charrow
Greenberg Traugott LLP
Barbara Culliton
Science Journalist and Policy Consultant
Elijah Cummings
U.S. House of Representatives
John Evans
Evans Telecommunications
Robert E. Fischell
Fischell Biomedical, LLC
Arthur Gajarsa
Retired, U.S. Court of Appeals
for the Federal District
Stewart Greenebaum
Greenebaum & Rose Associates, Inc.
William Hall
University College Dublin
Ernest F. Hollings
Former U.S. Senator
Harry Hulse
Harry Hulse Law Firm LLP
Mark Kaplan
University of Michigan Medical School
Sheilah A. Kast
Maryland Morning, WYPR
Nancy Kopp
Maryland State Treasurer
Ray Lewis
Former NFL Player
Henry Lowe
Bio-Tech R&D Institute Limited
Thomas Lynch
Amann Pharmaceutical, Ltd.
Princess Chulabhorn Mahidol
Mahidol University
Timothy Moynahan
Moynahan & Mirrella, LLC
Franco Nuschese
Georgetown Entertainment Group
Joseph S. Pagano
University of North Carolina
Peter Palese
Mount Sinai School of Medicine
James Pinkerton
RATE Coalition
Ellen Ratner
Talk Radio News Service
Stephanie Rawlings-Blake
Mayor of Baltimore
Edward "Chip" Robertson, Jr.
Bartimus Frickleton Robertson and Gomy
Raj Shah
CTIS, Inc.
Kathleen Kennedy Townsend
Former Lt. Governor of Maryland
Jeffrey Trammell
Trammell and Company
Lenny Wilkens
NBA Hall of Fame Coach and Player
Steven Wozencraft
John O'Donnell Associates, LLC
SCIENTIFIC ADVISORY BOARD
Joseph Pagano, (Chair)
University of North Carolina
Edward Berger
National Institutes of Health
Farley R. Cleghorn
Futures Group International
Myron S. Cohen
University of North Carolina
Max Essex
Harvard AIDS Institute
Warner C. Greene
Gladstone Institute of Virology
and Immunology
Mark H. Kaplan
University of Michigan Medical School
Michel Klein
VaxBio Inc
Erling C. J. Norrby
Secretary General, The Royal Swedish
Academy of Sciences
William Paul
National Institute of Allergy
and Infectious Diseases
Mario Stevenson
University of Miami
Sten Vermund
Vanderbilt University

725 West Lombard Street
Baltimore
MD 21201
USA
Tel: (+1) 410 706 6567
Email: lydiatang@ihv.umaryland.edu

Dear Editor,

I am pleased to resubmit for publication the revised version of manuscript no. 27437 "Safe and effective Sofosbuvir-based Therapy in Patients with Mental Health Disease". I appreciate the comments and suggestions of the reviewers and have addressed each of their concerns as outlined below.

Review 1:

Inclusion of more than one study keep non homogenized patient population with no clear inclusion and exclusion criteria. - Patient and methods are not clear, nor organized with lack of informations - Better not include abbreviations in paper title - Minor grammatical and spelling mistakes

Author response:

We thank the reviewer for the comments and suggestions. We have included the non-homogeneity of the patient populations in the limitations section of the discussion.

The inclusion and exclusion criteria from all studies included have been referenced.

The title has been changed from "Mental Health Disease and sofosbuvir-based therapy: high tolerability and SVR" to "Safe and effective Sofosbuvir-based Therapy in Patients with Mental Health Disease" to avoid abbreviations.

Grammatical and spelling mistakes have been corrected.

Reviewer 2:

Will you publish the change in BDI data in patients who did not achieve SVR? It could be of use as part of the BDI improvement could be related to improving physical condition or to knowing treatment is being effective.



INSTITUTE OF HUMAN VIROLOGY

Author response:

Due to the high efficacy of DAA-based therapy, we only have 1 patient who did not achieve SVR. Therefore, there was insufficient data to report on this study population.

Some abbreviations are not explained the first time they are used

Author response:

This has been corrected, thank you.

Although it is mentioned at the end, not including abuse disorders as mental health disease can overestimate adherence in the MHD patients' group. In treatment outcome it is stated that "the percentage of patients with MHD who achieved SVR was the same as those without MHD". From the data provided we know that there is not a statistically significant difference between those two groups, rather than being the same.

Author response:

This has been clarified. This sentence has been changed to "the percentage of patients with MHD who achieved SVR was not statistically different from those without MHD".

In patient adherence/pill count it looks like there is, in fact, a difference between the pill count patients with and without MHD, and that the comparison is insufficiently powered to show it. This should, probably, be referenced in the paragraph.

Author response:

This has been added to the limitations paragraph in the discussion

In discussion, fourth paragraph, it is stated that only one discontinuation from study could but attributed to MHD. You should maybe explain how was it determined.

Author response:

This has been clarified: "as determined by evaluation by the principal investigator" has been added to the end of this sentence.



INSTITUTE OF HUMAN VIROLOGY

There are some minor typos and small-in errors some of which are: Page four, lines 2-3 – “of those with mental health compared to...” Page four, lines 4-5 – “There was no statistically significant difference in pill counts nor in adherence to study visits between groups” Page fourteen, lines 21-22 – There is a typo in “psychiatric disease was identified as a predictor of nduring treatment” Page fifteen, line 12 – “among patients trated with a IFN-based therapy” Page fifteen, line 17 – “this study demonstrates that those patients with MHD”

Author response:

These have been corrected.

Editor comments:

Step 1. Please revise your manuscript according to the reviewers’ comments.

Author response:

This has been done.

Step 2. Please update the manuscript according to the Guidelines and Requirements for Manuscript Revision-Retrospective Cohort Study.

Author response:

This has been done

Step 3. Please provide the scientific research process.

Author response:

This has been completed and uploaded with this resubmission.

Step 4. Please provide an Audio Core Tip.

Author response:

This has been submitted.

Step 5. Please subject the manuscript to CrossCheck analysis and the final title to Google Scholar search, and store screenshot images of the results.

Author response:



INSTITUTE OF HUMAN VIROLOGY

We are agreeable to subjecting the manuscript to CrossCheck analysis. I have also performed a Google Scholar search of the title and have submitted the screen shots.

Step 6. Please provide the files related to academic rules and norms. The files related to academic rules and norms include the Institutional Review Board statement, informed consent statement, biostatistics statement, conflict-of-interest statement, and data sharing statement.

Author response:

These have all been uploaded with this resubmission.

Step 7. Please provide the approved grant application form(s) or funding agency copy of any approval document(s)/letter(s).

Author response:

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Step 8. Please revise the language of your manuscript. For manuscripts submitted by Non-Native Speakers of English, the authors are required to provide a language editing certificate, which will serve to verify that the language of the manuscript has reached Grade A.

Author response:

All authors are native speakers of English.

Step 9. Please sign the Copyright Assignment form.

Author response:

This has been submitted.

Thank you for considering our manuscript for publication in the World Journal of Gastroenterology.

Yours truly,

Lydia Tang, MBChB



INSTITUTE OF HUMAN VIROLOGY



725 West Lombard Street | Baltimore, Maryland 21201-1009 | 410.706.8614 | 410.706.1952 fax | www.ihv.org

Davidge Hall is the historical symbol of the **University of Maryland School of Medicine**—America's oldest public medical school, founded in 1807.